Company intelligence / Profile preview

Amicrobe, Inc.

Carlsbad, California, United Statespersportaal.anp.nl ↗

Ownership: Private
Employees: ~12
Development stage: Preclinical

Overview

Amicrobe has developed synthetic biologics called Amicidins that combine physical properties and microbicidal activity to combat pathogenic bacteria, fungi, and viruses. The company has produced clinical-grade Amicidins at kilogram-scale under GMP guidelines and is preparing for Phase 1/2a clinical trials.

Therapeutic areas: Infectious Diseases
Modalities: Synthetic biologicssynthetic proteins
Industry: Biotech

Drug pipeline

2 assets

Amicidin-β Solution

Pre-clinical

Indications: Surgical infections, Traumatic wound infections, Orthopedic hardware infections

1 more asset in the full pipeline.

Request access →

Partnerships

Polypeptide Therapeutic Solutions (PTS)

Beyond the preview

Go deeper on Amicrobe, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amicrobe, Inc..

Explore the full profile